Markus Sieger - 17 May 2023 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)

Reporting relationship: Director
Issuer ticker: CYTH
Reported as of: 17 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2023, 16:39:01 UTC
Prior SEC filing: 24 Apr 2023
Next SEC filing: 22 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Markus Sieger

Filing notes and source

Key filing fact

Markus Sieger filed Form 4 for Cyclo Therapeutics, Inc. (CYTH) on 18 May 2023.

Key facts

This page summarizes Markus Sieger's Form 4 filing for Cyclo Therapeutics, Inc. (CYTH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 May 2023, 16:39.

Change

Previous filing in this sequence was filed on 24 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYTH transaction

Common Stock

Award

Transaction value: $0
Shares: +42,962
Change %: +27%
Price: $0.000000
Shares after: 204,013
Date: 17 May 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2022 and first quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of 1.03 per share of common stock on May 16, 2023.